格莱梅皮里德/基基-β-环氧德克斯特林含有化合物:制备,表征和评估
Xin Quan1, Shurui Wang1, Jiamin Lu1
1Key Laboratory for Green Pharmaceutical Technologies and Related Equipment of Ministry of Education, College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Drug development and industrial pharmacy
|March 13, 2025
概括
这项研究使用由球磨加工制备的基基 (HP-β-CD) 纳入化合物增强了glimepiride (GM) 的溶解性和生物利用性. 这种新型配方显著改善了药物释放和药理动力学特征.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 物理化学 物理化学
背景情况:
- 格莱梅皮里德 (GM) 具有较差的溶解性和生物可用性,限制了其治疗疗效.
- 开发先进配方对于改善GM口服和患者治疗结果至关重要.
研究的目的:
- 准备和表征一个用优化球磨的glimepiride/hydroxypropyl-β-cyclodextrin (GM/HP-β-CD) 纳入化合物.
- 评估新型转基因/HP-β-CD纳入化合物的体外和体内性能.
主要方法:
- 使用响应表面方法来优化GM/HP-β-CD纳入化合物形成的球磨参数.
- 描述涉及粉末X射线衍射,DSC,SEM和FTIR;稳定性,体外溶解和体内药理学研究.
主要成果:
- 优化的球磨加工产生了稳定的GM/HP-β-CD纳入化合物,具有20倍更高的溶解度和12.7倍更快的溶解速度.
- 在体内研究表明,最大血度增加3.5倍,生物可用性显著提高,Tmax缩短.
结论:
- 通过球磨加工制备的GM/HP-β-CD纳入化合物显示出更好的溶解性,溶解性,稳定性和生物可用性.
- 这种配方有潜力用于持续释放的glimepiride,减少剂量频率并改善患者的遵守.
相关概念视频
Oral Hypoglycemic Agents: Glinides
124
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
124
Dipeptidyl Peptidase 4 Inhibitors
153
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
153
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
140
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
140
Glucagon-like Receptor Agonists
281
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
281
Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
Insulin: Biosynthesis, Chemistry, and Preparation
332
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
332


